Skip to main content
. Author manuscript; available in PMC: 2015 Jan 23.
Published in final edited form as: Cancer Res. 2010 Apr 13;70(8):3140–3149. doi: 10.1158/0008-5472.CAN-09-4456

Figure 1.

Figure 1

miR-483-3p and IGF2 expression in Wilms’ tumor. A, miR-483-3p relative expression analysis by quantitative real-time PCR on 19 samples of primary Wilms’ tumor, 3 adjacent non-tumoral tissues, fetal kidney, cell line HEK293, and fetal liver tissue. Each sample data was normalized to the endogenous reference RNU6B and related to the fetal kidney (calibrator) miR-483-3p expression (2−ΔΔCt method). B, different expressions from normal to tumoral tissue were pointed out in samples (WT_38, WT_39, and WT_40). C, Northern blot analysis of miR-483-3p and RNU6B in six Wilms’ tumor samples, two normal adult kidneys, one normal adult liver, and a HepG2 cell line. D, genomic structure of IGF2 gene (dark gray arrows) from the reference sequence AF517226; coding sequence (light gray arrows); miR-483 is indicated in the second IGF2 intron. Black bars (e and f) show the cDNA-amplified regions used to analyze IGF2 expression that was compared with the miR-483-3p expression in panels immediately below. IGF2 expression data were normalized on RNA 18S and related to IGF2 fetal kidney expression (2−ΔΔCt). R, correlation coefficients; P, P values.